Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.

Shim HJ, Kim HI, Lee ST.

Oncol Lett. 2017 Mar;13(3):1463-1469. doi: 10.3892/ol.2017.5564. Epub 2017 Jan 2.

2.

The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.

Mohyeldin MM, Akl MR, Siddique AB, Hassan HM, El Sayed KA.

Biochem Pharmacol. 2017 Feb 15;126:51-68. doi: 10.1016/j.bcp.2016.12.003. Epub 2016 Dec 8.

PMID:
27940262
3.

Signatures of Archaic Adaptive Introgression in Present-Day Human Populations.

Racimo F, Marnetto D, Huerta-Sánchez E.

Mol Biol Evol. 2017 Feb 1;34(2):296-317. doi: 10.1093/molbev/msw216.

4.

The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.

Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung MC, Lin C, Yang L.

Nat Cell Biol. 2016 Feb;18(2):213-24. doi: 10.1038/ncb3295. Epub 2016 Jan 11.

5.

PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.

Breast Cancer Res. 2015 Jun 19;17:86. doi: 10.1186/s13058-015-0594-z.

6.

Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.

Tsui T, Miller WT.

Biochemistry. 2015 May 26;54(20):3173-82. doi: 10.1021/acs.biochem.5b00303. Epub 2015 May 13.

7.

Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.

Fan G, Aleem S, Yang M, Miller WT, Tonks NK.

J Biol Chem. 2015 Jun 26;290(26):15934-47. doi: 10.1074/jbc.M115.651703. Epub 2015 Apr 20.

8.

Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.

Falkenberg N, Anastasov N, Höfig I, Bashkueva K, Lindner K, Höfler H, Rosemann M, Aubele M.

Mol Oncol. 2015 Jan;9(1):282-94. doi: 10.1016/j.molonc.2014.08.012. Epub 2014 Sep 6.

9.

Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Hussain HA, Harvey AJ.

World J Clin Oncol. 2014 Aug 10;5(3):299-310. doi: 10.5306/wjco.v5.i3.299. Review.

10.

HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.

Pires IM, Blokland NJ, Broos AW, Poujade FA, Senra JM, Eccles SA, Span PN, Harvey AJ, Hammond EM.

Cancer Biol Ther. 2014 Oct;15(10):1350-7. doi: 10.4161/cbt.29822. Epub 2014 Jul 14.

11.

PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.

Ono H, Basson MD, Ito H.

PLoS One. 2014 May 1;9(5):e96060. doi: 10.1371/journal.pone.0096060. eCollection 2014.

12.
13.

BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.

Miah S, Goel RK, Dai C, Kalra N, Beaton-Brown E, Bagu ET, Bonham K, Lukong KE.

PLoS One. 2014 Feb 11;9(2):e87684. doi: 10.1371/journal.pone.0087684. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98814.

14.

Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.

Peng M, Ball-Kell SM, Franks RR, Xie H, Tyner AL.

Oncogenesis. 2013 Dec 9;2:e81. doi: 10.1038/oncsis.2013.43.

15.

Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.

Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schörg A, Hoogewijs D, Wenger RH, Seagroves TN, Lange CA.

Cancer Res. 2013 Sep 15;73(18):5810-20. doi: 10.1158/0008-5472.CAN-13-0523. Epub 2013 Aug 8. Erratum in: Cancer Res. 2013 Nov 1;73(21):6538.

16.

PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer.

Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, Macias V, Kajdacsy-Balla A, Tyner AL.

Cancer Res. 2013 Sep 1;73(17):5426-37. doi: 10.1158/0008-5472.CAN-13-0443. Epub 2013 Jul 15. Erratum in: Cancer Res. 2013 Oct 1;73(19):6096.

17.

Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.

Fan G, Lin G, Lucito R, Tonks NK.

J Biol Chem. 2013 Aug 23;288(34):24923-34. doi: 10.1074/jbc.M113.482737. Epub 2013 Jun 28.

18.

HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.

Ai M, Qiu S, Lu Y, Fan Z.

Cell Signal. 2013 Sep;25(9):1754-61. doi: 10.1016/j.cellsig.2013.05.010. Epub 2013 May 22.

19.

Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.

Miah S, Martin A, Lukong KE.

Oncogenesis. 2012 May 7;1:e11. doi: 10.1038/oncsis.2012.11.

20.

Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma.

Liu XK, Zhang XR, Zhong Q, Li MZ, Liu ZM, Lin ZR, Wu D, Zeng MS.

J Transl Med. 2013 Mar 7;11:59. doi: 10.1186/1479-5876-11-59.

Supplemental Content

Support Center